Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.71 |
| ▸ | MAPT | P10636 | 6/20 | 0.71 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | MPI | P34949 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4008558 | 0.92 | ALDH1A1 (0.63) | ALDH1A1KMT2AMAPTTP53ALDH3A1 | |
| SCHEMBL17033399 | 0.85 | ALDH1A1 (0.69) | ALDH1A1KMT2AMAPTTP53HTT | |
| SCHEMBL12123785 | 0.84 | ALDH1A1 (0.70) | ALDH1A1KMT2AMAPTTP53ALDH3A1 | |
| SCHEMBL21643561 | 0.84 | ALDH1A1 (0.69) | ALDH1A1KMT2AMAPTTP53ALDH3A1 | |
| SCHEMBL12123811 | 0.84 | ALDH1A1 (0.69) | ALDH1A1KMT2AMAPTTP53ALDH3A1 | |
| SCHEMBL12123776 | 0.84 | ALDH1A1 (0.69) | ALDH1A1KMT2AMAPTTP53ALDH3A1 | |
| SCHEMBL12123780 | 0.84 | ALDH1A1 (0.69) | ALDH1A1KMT2AMAPTTP53ALDH3A1 | |
| Hydrochloric Acid SCHEMBL7930366 | 0.83 | ALDH1A1 (0.70) | ALDH1A1KMT2AMAPTTP53ALDH3A1 | |
| Hydrochloric Acid SCHEMBL7929072 | 0.83 | ALDH1A1 (0.70) | ALDH1A1KMT2AMAPTTP53ALDH3A1 | |
| Hydrochloric Acid SCHEMBL7934870 | 0.83 | ALDH1A1 (0.70) | ALDH1A1KMT2AMAPTTP53ALDH3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436183-B2 | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-8436183-B2 | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-8436183-B2 | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120130076-A1 | Synthetic Multimerizing Agents | ARIAD PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120130076-A1 | Synthetic Multimerizing Agents | ARIAD PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120130076-A1 | Synthetic Multimerizing Agents | ARIAD PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-8106191-B2 | Compounds based on N- acyl-pipecolyl and N-acyl-prolyl ligand moieties for multimerizing chimeric proteins containing immunophilin-derived domains | ARIAD PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106191-B2 | Compounds based on N- acyl-pipecolyl and N-acyl-prolyl ligand moieties for multimerizing chimeric proteins containing immunophilin-derived domains | ARIAD PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106191-B2 | Compounds based on N- acyl-pipecolyl and N-acyl-prolyl ligand moieties for multimerizing chimeric proteins containing immunophilin-derived domains | ARIAD PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| EP-0888303-B1 | SYNTHETIC DERIVATIVES OF RAPAMYCIN AS MULTIMERIZING AGENTS FOR CHIMERIC PROTEINS WITH IMMUNOPHILIN-DERIVED DOMAINS | ARIAD PHARMA INC (US) | 2010-04-21 | — | — | EP | disclosed |
| US-20040006233-A1 | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. | 2004-01-08 | — | — | US | disclosed |
| US-20030036654-A1 | Synthetic multimerizing agents | HOLT DENNIS A (US) | 2003-02-20 | — | — | US | disclosed |
| US-20020161240-A1 | Synthetic multimerizing agents | ARIAD GENE THERAPEUTICS, INC. | 2002-10-31 | — | — | US | disclosed |
| US-6150527-A | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6133456-A | DIMERS OF THE MACROCYCLIC NATURAL PRODUCT, FK506, COVALENTLY ATTACHED TO EACH OTHER VIA A SYNTHETIC LINKER MOIETY | ARIAD GENE THERAPEUTICS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| EP-0888303-A1 | SYNTHETIC DERIVATIVES OF RAPAMYCIN AS MULTIMERIZING AGENTS FOR CHIMERIC PROTEINS WITH IMMUNOPHILIN-DERIVED DOMAINS | ARIAD GENE THERAPEUTICS, INC. (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997031898-A1 | SYNTHETIC DERIVATIVES OF RAPAMYCIN AS MULTIMERIZING AGENTS FOR CHIMERIC PROTEINS WITH IMMUNOPHILIN-DERIVED DOMAINS | ARIAD GENE THERAPEUTICS, INC. (US) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161240-A1 | Synthetic multimerizing agents | SSB, F13B, LCP2 | ALDH1A1 4421/4885KMT2A 2738/4885MAPT 3133/4885 |
| US-20120130076-A1 | Synthetic Multimerizing Agents | FKBP1B, FKBP2, FKBP14 | ALDH1A1 4766/4885KMT2A 1904/4885MAPT 1486/4885 |
| US-20040006233-A1 | Synthetic multimerizing agents | FKBP1B, FKBP2, FKBP14 | ALDH1A1 4740/4885KMT2A 1992/4885MAPT 1391/4885 |
| US-20030036654-A1 | Synthetic multimerizing agents | FKBP1B, FKBP2, FKBP14 | ALDH1A1 4760/4885KMT2A 1864/4885MAPT 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.